デフォルト表紙
市場調査レポート
商品コード
1318852

全身性エリテマトーデス市場:薬剤タイプ、ドラッグデリバリー方式別-2023~2030年の世界予測

Systemic Lupus Erythematosus Market by Drug Type, Mode of Delivery - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 185 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.49円
全身性エリテマトーデス市場:薬剤タイプ、ドラッグデリバリー方式別-2023~2030年の世界予測
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 185 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

全身性エリテマトーデスの世界市場は、2023年にCAGR 10.47%で20億4,387万米ドルが予測され、2030年には41億2,270万米ドルに達するという驚異的な成長を遂げると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の全身性エリテマトーデス市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます:フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します:

1.市場の浸透度:主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展:有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化:新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向:COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報:主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション:将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします:

1.全身性エリテマトーデスの世界市場規模および予測は?

2.予測期間中、世界の全身性エリテマトーデス市場を形成するCOVID-19の阻害要因と影響は?

3.全身性エリテマトーデスの世界市場において予測期間中に投資すべき製品/セグメント/用途/分野は?

4.全身性エリテマトーデスの世界市場における競争戦略は?

5.全身性エリテマトーデスの世界市場における技術動向と規制の枠組みは?

6.全身性エリテマトーデスの世界市場における主要ベンダーの市場シェアは?

7.全身性エリテマトーデスの世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 全身性エリテマトーデスの普及率が世界中で増加
      • 炎症性自己免疫疾患と治療に対する意識の高まり
      • ヘルスケアインフラとループス治療クリニックの改善
    • 抑制要因
      • 低所得国における高額な治療費とインフラ不足
    • 機会
      • ループス研究活動への多額の資金提供と投資
      • 治療技術の進歩と新製品の発売
    • 課題
      • 治療における合併症および全身性エリテマトーデス管理におけるその他の困難
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 全身性エリテマトーデス市場:薬剤タイプ別

  • イントロダクション
  • B細胞モジュレーター
  • 抗マラリア薬
    • クロロキン
    • ヒドロクロロキン
  • 生物製剤
    • 全身性エリテマトーデスの治療用に承認された生物製剤
      • B細胞標的療法
      • Blysブロッカー(ベリムマブ)
    • 適応外で使用される生物製剤
  • 細胞毒性薬および免疫抑制薬
    • シクロホスファミド
    • シクロスポリン
    • メトトレキサート
    • ミコフェノール酸モフェチルまたはタクロリムス
  • 免疫抑制薬、細胞毒性薬、T細胞モジュレーター
  • 非ステロイド性抗炎症薬
  • 炎症誘発性およびサイトカイン阻害剤

第7章 全身性エリテマトーデス市場:ドラッグデリバリー方式別

  • イントロダクション
  • 静脈内
  • 経口
  • 皮下
  • 局所

第8章 南北アメリカの全身性エリテマトーデス市場

  • イントロダクション
  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域の全身性エリテマトーデス市場

  • イントロダクション
  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカの全身性エリテマトーデス市場

  • イントロダクション
  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析:主要企業別
  • 競合シナリオ分析:主要企業別

第12章 掲載企業一覧

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET RESEARCH PROCESS
  • FIGURE 2. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2022 VS 2030 (%)
  • FIGURE 5. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2022 VS 2030 (%)
  • FIGURE 6. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 7. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET DYNAMICS
  • FIGURE 8. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 9. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 15. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 5. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY B-CELL MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 7. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CHLOROQUINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY HYDROCHLOROQUINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 11. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 13. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY B-CELL TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BLYS-BLOCKERS (BELIMUMAB), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS USED OFF-LABEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 18. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYCLOSPORINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MYCOPHENOLATE MOFETIL OR TACROLIMUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY IMMUNOSUPPRESSIVE & CYTOTOXIC DRUGS & T-CELL MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS , BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY PRO-INFLAMMATORY & CYTOKINE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 27. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 281. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 282. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 283. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET LICENSE & PRICING
目次
Product Code: MRR-957C47F944D8

The Global Systemic Lupus Erythematosus Market is forecasted to grow significantly, with a projected USD 2,043.87 million in 2023 at a CAGR of 10.47% and expected to reach a staggering USD 4,122.70 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Systemic Lupus Erythematosus Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Systemic Lupus Erythematosus Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug Type, market is studied across B-Cell Modulators, Antimalarial Drugs, Biologics, Cytotoxic & Immunosuppressive Drugs, Immunosuppressive & Cytotoxic Drugs & T-Cell Modulators, Non-Steroidal Anti-Inflammatory Drugs, and Pro-Inflammatory & Cytokine Inhibitors. The Antimalarial Drugs is further studied across Chloroquine and Hydrochloroquine. The Biologics is further studied across Approved Biologics for Treating SLE and Biologics Used Off-Label. The Approved Biologics for Treating SLE is further studied across B-Cell Targeted Therapy and Blys-Blockers (Belimumab). The Cytotoxic & Immunosuppressive Drugs is further studied across Cyclophosphamide, Cyclosporine, Methotrexate, and Mycophenolate Mofetil or Tacrolimus. The Antimalarial Drugs is projected to witness significant market share during forecast period.

Based on Mode of Delivery, market is studied across Intravenous, Oral, Subcutaneous, and Topical. The Subcutaneous is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.74% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Systemic Lupus Erythematosus Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Systemic Lupus Erythematosus Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Systemic Lupus Erythematosus Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Systemic Lupus Erythematosus Market?

4. What is the competitive strategic window for opportunities in the Global Systemic Lupus Erythematosus Market?

5. What are the technology trends and regulatory frameworks in the Global Systemic Lupus Erythematosus Market?

6. What is the market share of the leading vendors in the Global Systemic Lupus Erythematosus Market?

7. What modes and strategic moves are considered suitable for entering the Global Systemic Lupus Erythematosus Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Systemic Lupus Erythematosus Market, by Drug Type, 2022 vs 2030
  • 4.3. Systemic Lupus Erythematosus Market, by Mode of Delivery, 2022 vs 2030
  • 4.4. Systemic Lupus Erythematosus Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of systemic lupus erythematosus worldwide
      • 5.1.1.2. Rising awareness of inflammatory autoimmune diseases and treatment
      • 5.1.1.3. Improvement in healthcare infrastructure and lupus treatment clinics
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment and lack of infrastructure in low-income countries
    • 5.1.3. Opportunities
      • 5.1.3.1. Significant funding and investment for lupus research activities
      • 5.1.3.2. Advancement in treatment technologie and launch of new products
    • 5.1.4. Challenges
      • 5.1.4.1. Complications in treatment and other difficulties in managing SLE
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Systemic Lupus Erythematosus Market, by Drug Type

  • 6.1. Introduction
  • 6.2. B-Cell Modulators
  • 6.3. Antimalarial Drugs
    • 6.3.1. Chloroquine
    • 6.3.2. Hydrochloroquine
  • 6.4. Biologics
    • 6.4.1. Approved Biologics for Treating SLE
      • 6.4.1.1. B-Cell Targeted Therapy
      • 6.4.1.2. Blys-Blockers (Belimumab)
    • 6.4.2. Biologics Used Off-Label
  • 6.5. Cytotoxic & Immunosuppressive Drugs
    • 6.5.1. Cyclophosphamide
    • 6.5.2. Cyclosporine
    • 6.5.3. Methotrexate
    • 6.5.4. Mycophenolate Mofetil or Tacrolimus
  • 6.6. Immunosuppressive & Cytotoxic Drugs & T-Cell Modulators
  • 6.7. Non-Steroidal Anti-Inflammatory Drugs
  • 6.8. Pro-Inflammatory & Cytokine Inhibitors

7. Systemic Lupus Erythematosus Market, by Mode of Delivery

  • 7.1. Introduction
  • 7.2. Intravenous
  • 7.3. Oral
  • 7.4. Subcutaneous
  • 7.5. Topical

8. Americas Systemic Lupus Erythematosus Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Systemic Lupus Erythematosus Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Systemic Lupus Erythematosus Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing